Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatment of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC); MIV-711, a potent and selective cathepsin K inhibitor that is in a Phase II trial for the treatment of osteoarthritis, as well as in Phase I trials for the treatment of Osteogenesis Imperfecta (brittle bone disease) and Legg-Calvé-Perthes disease (LCPD); and fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication, which is in Phase I and II trials for the treatment of hepatocellular carcinoma. In addition, the company is developing birinapant, a SMAC-mimetic for the treatment of solid tumors; VBX-1000 (MIC-701), a selective cathepsin K inhibitor for the treatment of canine periodontitis; USP-7, a preclinical research program for the treatment of cancer; and MET-X (MBLI), a preclinical project for the treatment of infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.